Search
Close this search box.

Dr. Lee’s Mission: A Promising Future For Children With Advanced Ewing Sarcoma – Renal.PlatoHealth.ai

The prognosis for children with metastatic Ewing sarcoma can be devastating. Dr. Lee’s research may change that.

In a groundbreaking development for pediatric Ewing sarcoma research, we’re excited to share with you our latest funded researcher, Dr. Lee of the David Geffen School of Medicine at UCLA. His team’s novel approach may offer a new, precise treatment approach for this aggressive disease.

Dr. John Lee
Dr. John Lee, associate professor in residence in the Division of Hematology/Oncology at the David Geffen School of Medicine at UCLA

What makes metastatic Ewing sarcoma so devastating?

Ewing sarcoma is a bone cancer that can be difficult to treat once it has spread. The 5-year survival rate for children with the advanced disease remains alarmingly poor, as low as 15%. Children with ES need new treatment options now. This milestone underscores the urgency of advancing innovative treatments for ES and reflects the ongoing commitment to driving progress in pediatric cancer research

Dr. Lee’s preclinical work is focused on harnessing the power of CAR T-cell therapy. His team’s method goes a step further by enhancing the potency of CAR T-cells through the strategic incorporation of Interleukin-18 (IL-18), a cytokine known for its ability to bolster immune responses. By arming these CAR T cells with Interleukin-18 (IL-18), Dr. Lee aims to significantly enhance their killing ability, potentially improving outcomes for patients with metastatic ES, who face a dire prognosis due to the disease’s poor overall survival rates.

About Dr. Lee and team’s groundbreaking project

Dr. Lee says, “Our hope is this treatment can one day lead to better outcomes for kids with this disease by making their immune systems better at fighting the cancer.”

We’re committed to investing over $900,000 in Dr. Lee’s project to accelerate ES research

Our Acceleration Initiative projects are highly innovative, address a significant challenge in pediatric cancer drug development, and have an extremely strong probability of clinical application in an accelerated timeframe – anticipated to reach clinic within 3 years.

You make our funding of this groundbreaking project possible!

Collaboration leads to cures

As part of our growing co-funding model, this award is generously supported in part by Rally Foundation for Childhood Cancer Research and three CureSearch Legacy Funds: Garret and I: The Garret Collins Legacy Fund, The Nick Currey Fund, and The Sam Schneider Legacy.

Our legacy fund program provides families a personal and impactful way to honor their child’s journey by directly funding the most promising childhood cancer research. Learn more about starting a legacy fund here.